Lyme Disease and other Tick-Borne Diseases
Customize your policy alerts
Sign up for Aetna Policy 0215 alerts
Get alerted when Policy 0215 changes without checking for updates manually.
Monitor payer policy activity
This Aetna clinical policy bulletin governs medical necessity and coverage for intravenous antibiotic therapy, diagnostic testing, and other treatments related to Lyme disease and selected tick-borne diseases for insured members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Lyme Disease and Selected Tick‑Borne Diseases
Initial Therapy
Covered when ALL of the following are met
CDC two-test approach; see Western blot band criteria in policy
Each listed organ-specific manifestation qualifies
Repeat Therapy
Covered when ALL of the following are met
Allows one repeat 4-week course
Experimental / Investigational / Not Medically Necessary
Policy lists many specific tests and therapies considered experimental/investigational
Initial/Standard therapy coverage
Covered when ALL of the following are met (per evidence/guideline statements in document):
Supported by guideline statements
CDC and guideline guidance
Supported by AAN/EFNS and UpToDate summaries
Unproven / Not medically necessary indications
Not covered / not supported when ANY of the following are present:
Randomized trials show no sustained benefit
Seropositivity without symptoms does not justify antibiotics
Treatment recommendations for Lyme neuroborreliosis and Lyme arthritis
Covered when criteria below are met:
Children treated as adults except doxycycline contraindicated under age 8
Multiple ambulatory trials support short-course oral therapy
Gaubitz summary
Therapy modality and prolonged IV therapy evidence
Covered when specific clinical indications are met (per guideline summaries and trials):
UpToDate and guideline summaries
IDSA/AAN/ACR guideline draft and UpToDate
Klempner trials and others
Diagnostics: serology, biomarkers, and investigational urine OspA
Diagnostic confirmation and investigational diagnostics:
Gaubitz; diagnostic guidance
Systematic review identified 26 studies
Magni et al study
Testing ticks for Borrelia burgdorferi or other organisms is considered experimental/investigational and is not a medically useful sole basis for deciding treatment. Encounters coded for screening based on testing ticks (e.g., ICD-10 Z11.2, Z11.8) are identified in the policy as not indicated; scheduled repeated testing of ticks or repeat testing without a change in the member's signs or symptoms is not medically necessary.
Polymerase chain reaction (PCR) testing for B. burgdorferi DNA or RNA has not been validated for routine diagnosis or for monitoring response to therapy and remains a research technique. PCR may be corroborative only in limited contexts (for example, symptom duration <6 weeks when antibodies may be absent), but routine clinical use is not recommended due to concerns about contamination, limited clinical-series data, and lack of standardization.
Single photon emission computed tomographic (SPECT) brain scans are unreliable for diagnosing nervous system Lyme disease: qualitative SPECT is highly variable, shows no pattern specific to Lyme disease, and has no established positive or negative predictive value. Therefore SPECT (and similar perfusion imaging used qualitatively) is not recommended as a diagnostic test for nervous system Lyme disease.
There is no high-quality evidence to support long-term combined antibiotic regimens or other unproven therapies (for example, combined prolonged antibiotics or Antibiotic Augmented Thermo‑Eradication) as established treatments for Lyme arthritis or chronic/post‑treatment Lyme presentations. Reports of patient-reported benefit exist for some novel approaches, but these are uncontrolled and insufficient to support routine use; combined or prolonged regimens are therefore considered unsupported by the evidence.
Contemporary guideline summaries and reviews do not recommend intramuscular penicillin or routine long-term combined antibiotic treatments as preferred therapeutic options. Intramuscular antibiotics are not described as standard therapy in current guideline sources, and long-term combined antibiotic approaches lack reproducible evidence of benefit and are not recommended for routine clinical use.
The CDC and guideline panels advise against certain laboratory methods for clinical use because they lack independent, reproducible validation. Examples include urine antigen capture assays, DNA testing modalities not standardized for routine use, lymphocyte transformation tests, and quantitative CD57 lymphocyte assays; these methods should be avoided in routine clinical practice pending further validation.
This Clinical Policy Bulletin provides a partial, general description of plan or program benefits and is not a contract. Coverage determinations remain subject to the member’s plan terms; the bulletin is intended to assist in administering plan benefits but does not guarantee coverage or constitute medical advice.
Long-term intravenous antibiotic therapy is generally not medically necessary for immunocompetent persons with Bartonella-associated vasculo-proliferative disease or Bartonella bacteremia (except in endocarditis or severe systemic infection), and IV therapy for Q fever is considered experimental. These indications are not supported for routine prolonged IV therapy.
Prolonged, repeated, or chronic parenteral antibiotic therapy for 'chronic Lyme disease' or for persistent nonspecific post‑Lyme symptoms lacking objective evidence of active infection is not supported. Randomized trials and cohort data show no sustained benefit and document meaningful risks and adverse events from extended antibiotic courses.
Prolonged antibiotic re-treatment (beyond recommended courses) for persistent, unexplained symptoms attributed to prior Lyme disease has not demonstrated consistent benefit in randomized controlled trials. Multiple high-quality trials and reviews found no durable improvement with extended antibiotic retreatment and highlighted significant treatment-related harms.
Use of investigational diagnostic tests — including SPECT, PET, iSpot/ELISPOT and modified interferon‑gamma assays, lymphocyte proliferation assays, and other experimental immune- or biomarker-based tests — lacks sufficient evidence for routine diagnostic use. Available studies report variable performance and are not adequate to support these tests as standard diagnostic modalities for Lyme disease.
Prolonged courses of IV antibiotics (extended re‑treatment) for persistent post‑treatment Lyme symptoms have not shown consistent benefit in randomized trials and may be associated with severe adverse events. The evidence does not support routine extended IV antibiotic retreatment for post‑treatment symptoms.
Alternative nonpharmacologic or unconventional therapies (for example, oxygen/reactive-oxygen therapy, energy- and radiation-based therapies, and other listed interventions) have not demonstrated benefit for chronic Lyme-related symptoms in available reports and, in some settings, have been harmful; these approaches are not supported as standard treatment.
Coding Guidance and Applicable Codes
| 0041U | Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM. |
| 0042U | Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG. |
| 0043U | Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM. |
| 0044U | Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG. |
| 84181 | Western Blot, with interpretation and report, blood or other body fluid. |
| 84182 | Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each. |
| 86617 | Borrelia burgdorferi (Lyme disease) confirmatory test (e.g., Western Blot or immunoblot). |
| 86618 | Borrelia burgdorferi (Lyme disease). |
| 88346 | Immunofluorescence, per specimen; initial single antibody stain procedure. |
| 88350 | Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure). |
| 0232T | Injection(s), platelet rich plasma, any site. |
| 0316U | Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine. |
| 77401-77417 | Radiation treatment delivery (not covered). |
| 78608-78609 | Brain imaging, PET; metabolic or perfusion evaluation (not covered). |
| 78811-78816 | Positron emission tomography (PET) (not covered). |
| 82136 | Amino acids, 2 to 5 amino acids, quantitative (not covered). |
| 82533 | Cortisol; total (not covered). |
| 82626 | Dehydroepiandrosterone (DHEA) (not covered). |
| 83088 | Histamine (not covered). |
| 83497 | Hydroxyindolacetic acid, 5-(HIAA) (not covered). |
| G0068 | Professional services for the administration of anti-infective, pain management, chelation, pulmonary hypertension, and/or inotropic infusion drug(s) for each infusion drug administration calendar day in the individual's home, each 15 minutes. |
| S9494-S9504 | Home infusion therapy, antibiotic, antiviral, or antifungal therapy. |
| A69.20-A69.29 | Lyme disease (covered if selection criteria are met). |
| A28.1 | Cat-scratch disease (not covered). |
| A44.0-A44.9 | Bartonellosis (not covered). |
| A78 | Q fever (not covered). |
| B60.0 | Babesiosis (not covered). |
| G51.0 | Bell's palsy (not covered). |
| R53.82 | Chronic fatigue, unspecified (not covered). |
| Z11.2 | Encounter for screening for other bacterial diseases (testing ticks not covered). |
| Z11.8 | Encounter for screening for other infectious and parasitic diseases (testing ticks not covered). |
Provider Actions, Prior Authorization, and Documentation Requirements
Prior authorization for outpatient IV antibiotics/infusion services
Prior authorization is required for outpatient IV antibiotic therapy and home infusion services. Outpatient IV antibiotic therapy is covered only when selection criteria for a definitive diagnosis of Lyme disease are documented and medical-necessity criteria for initial or repeat IV therapy are met (see diagnostic documentation and medical necessity criteria).
- Affected services: outpatient IV antibiotic infusion administration and home infusion service codes (e.g., CPT 96365–96368 series as applicable).
- Prior authorization applies before initiation of outpatient/home IV therapy.
IV ceftriaxone for CNS disease or persistent Lyme arthritis
Parenteral ceftriaxone (2 g once daily in adults; weight‑based dosing in children) is the recommended IV agent for patients with central nervous system (CNS) Lyme disease (neuroborreliosis) and for patients with Lyme arthritis who fail an appropriate course of oral therapy. Documentation must show indication (CNS disease or oral-treatment failure) and prior authorization when outpatient IV therapy is requested.
- IV ceftriaxone dosing: 2 g IV daily in adults; pediatric dosing 50–75 mg/kg IV once daily as clinically indicated.
- Indications: CNS manifestations (e.g., encephalitis, confirmed meningitis with CSF evidence) or persistent Lyme arthritis after adequate oral therapy.
IV therapy for cardiac indications
IV antibiotic therapy is recommended for hospitalized patients with symptomatic Lyme carditis with high‑grade atrioventricular block or marked PR prolongation. When IV therapy is required, ceftriaxone (2 g IV once daily in adults) is the preferred agent; continue IV therapy until high‑grade AV block resolves and PR interval is < 300 ms, then switch to oral therapy to complete total recommended duration.
- Indications for IV: syncope, dyspnea, chest pain, second- or third-degree AV block, or first-degree AV block with markedly prolonged PR interval (≥300 ms).
- Transition: after resolution of high-grade block/PR <300 ms, switch to oral antibiotics (doxycycline, amoxicillin, or cefuroxime) to complete 21–28 day course.
IV vs oral antibiotic therapy
Oral antibiotic therapy is preferred over IV in most circumstances because oral regimens have equivalent efficacy, better tolerability, and lower cost. IV therapy is reserved for specific indications (e.g., hospitalized patients, CNS involvement, severe carditis, or failure of oral therapy).
- Oral doxycycline (200 mg daily) is effective for erythema migrans and for many cases of early neurologic Lyme disease in ambulatory patients.
- Reserve IV therapy for parenchymal CNS disease, severe neurologic symptoms, hospitalized patients, or oral-treatment failures.
Prior authorization not specified in this section
This section does not specify exact prior authorization code lists or detailed procedural steps for obtaining authorization. Providers should follow the payer's standard prior authorization submission process and include the required clinical documentation described below.
- Prior authorization requirement is noted, but check payer portal or contact for current code list and submission instructions.
IV antibiotic therapy is experimental/investigational for certain indications
IV antibiotic therapy is considered experimental and investigational (and therefore not covered) for certain indications where benefit has not been established, including early Lyme disease, new-onset Lyme arthritis, nonspecific flu‑like syndromes, chronic fatigue syndromes, and asymptomatic persons with only positive serology.
- Examples of non-covered/experimental IV indications: early localized Lyme disease, isolated Bell's palsy without other evidence of dissemination, prophylaxis for asymptomatic persons with only positive immunologic tests, mild cardiac involvement (e.g., PR <0.4 s without heart failure), and persistent nonspecific symptoms attributed to Lyme disease (post‑treatment syndromes).
Risk of denial for inappropriate testing or prolonged antibiotic therapy
Requests for testing or prolonged antibiotic therapy may be denied when the pretest probability is low, when testing or treatment is not supported by objective findings, or when prolonged/repeated antibiotic courses lack evidence of sustained benefit and carry known risks.
- Risk factors for denial: ordering serologic tests for nonspecific symptoms without objective signs, initiating antibiotics based solely on positive serology without compatible clinical findings, and requesting repeated/prolonged IV antibiotics for post‑treatment symptoms without objective evidence of ongoing infection.
Requests for long-term or combined antibiotics
Requests for long‑term or combined antibiotic regimens for Lyme disease are not supported by evidence and are generally not recommended; documentation must justify any deviation from standard recommended durations and single‑agent therapy.
- There is no evidence to recommend long‑term (> standard course) or combined antibiotic treatments for Lyme arthritis or other Lyme manifestations.
- Combined antibiotics are not mentioned as a therapeutic option in major reviews and guidelines.
Requests for prolonged antibiotic therapy
Re‑treatment or prolonged antibiotic courses for persistent symptoms attributed to Lyme disease (post‑treatment Lyme syndromes) have not demonstrated sustained benefit in randomized trials and are associated with adverse events; such requests are likely to be denied without objective evidence of relapse or new organ involvement.
- Evidence: randomized trials show no durable benefit for prolonged IV antibiotics in post‑Lyme fatigue or encephalopathy and note higher adverse event rates.
- A single repeat 4‑week IV course may be considered only when strict criteria for relapse or progression are met and prior documentation is provided.
Clinical Policy Bulletins constitute only a partial, general description of plan benefits
Clinical Policy Bulletins are developed to assist in administering plan benefits and constitute only a partial, general description of plan benefits; they do not constitute a contract and are not medical advice. Treating providers are solely responsible for medical advice and treatment of members.
- This bulletin may be updated and is subject to change.
- Participating providers are independent contractors; Aetna does not provide health care services or guarantee outcomes.
Required diagnostic documentation for Lyme disease and neuroborreliosis
Required diagnostic documentation for Lyme disease and neuroborreliosis must include objective signs and validated laboratory support. For neuroborreliosis, document CSF findings consistent with intrathecal antibody production or other confirmatory CSF evidence.
- Lyme disease diagnosis: objective signs (erythema migrans or late manifestation) plus serologic testing (EIA/IFA followed by Western blot with CDC criteria).
- Neuroborreliosis: CSF pleocytosis and evidence of intrathecal Borrelia antibody production (CSF-to-serum antibody ratio >1.0) or other supportive CSF findings.
Diagnostic documentation
Diagnostic confirmation should correlate laboratory results with clinical presentation. Positive ELISA should be followed by IgG immunoblot; PCR positivity from synovial fluid adds diagnostic certainty for Lyme arthritis. Positive serology alone does not justify antibiotic therapy without compatible signs/symptoms.
- Follow CDC two‑step testing (sensitive EIA/IFA then Western blot); interpret IgM results cautiously beyond 1 month's duration.
- Synovial fluid PCR and positive ELISA + IgG immunoblot increase diagnostic certainty for Lyme arthritis.
Clinical correlation for novel diagnostics
When using novel or nonstandard diagnostics, include clinical correlation and confirmatory testing. Some tests (e.g., urine OspA, antigen capture assays, nonstandard serology interpretations) are not recommended by CDC/IDSA and should be interpreted with caution and accompanied by standard validated tests and clinical findings.
- CDC does not recommend urine antigen capture assays; IDSA advises avoiding certain commercially available nonstandard tests lacking validation (e.g., urine antigen, nonstandard serology interpretation, lymphocyte transformation test, CD57 assays).
- Provide clinical context (objective signs, symptom timing) when novel tests are submitted for review.
Treating providers are responsible for medical advice and treatment
Treating providers are responsible for medical advice and treatment. The policy provides guidance for coverage determinations but does not replace clinical judgment.
- Providers must supply complete clinical documentation to support medical necessity and prior authorization requests.
- Aetna is not responsible for clinical care decisions; participating providers are independent contractors.
Step from oral doxycycline to IV ceftriaxone
Switching from oral doxycycline to IV ceftriaxone is appropriate when patients with Lyme disease fail to respond to an adequate oral course or when clinical severity mandates parenteral therapy (e.g., CNS parenchymal disease, severe carditis). Oral doxycycline (200 mg daily) is effective for many ambulatory early neurologic cases; IV ceftriaxone is indicated for treatment failures or more severe disease.
- Oral doxycycline dosing: 200 mg once daily (or 100 mg twice daily) for erythema migrans and many early neurologic cases.
- IV ceftriaxone indicated for failure of oral therapy, parenchymal CNS involvement, or other severe manifestations.
Oral-before-IV preference
Guideline preference is oral-before-IV: oral therapy is effective and preferred in most circumstances. Step‑therapy principles favor initiating oral antibiotics for appropriate presentations before escalating to IV, except when IV is clearly indicated (hospitalized patients, severe neurologic or cardiac disease).
- Oral-before-IV preference is supported by guidelines emphasizing equivalent efficacy of oral regimens for many presentations and reserving IV for specific indications.
- When documentation shows a clear indication for immediate IV therapy (e.g., high‑grade AV block, CNS parenchymal disease), prior authorization should cite the indication.
Step therapy preference for oral antibiotics / No step therapy requirements are provided
While guideline-based step‑therapy preference favors oral regimens first, this policy does not establish a formal administrative step‑therapy program with mandated prior authorization sequences beyond standard prior authorization requirements; clinical exceptions apply when IV therapy is immediately indicated.
- No formal step‑therapy administrative requirements are specified in this section; follow standard prior authorization processes and document clinical rationale for IV initiation when applicable.
Background and Evidence Summary
The appropriate use and duration of IV antibiotics for Lyme disease is controversial. Evidence from randomized trials and cohort studies supports short, guideline-recommended courses for specific indications (for example, oral doxycycline for erythema migrans and IV ceftriaxone 2 g/day for neurologic or severe disease). Randomized trials of prolonged IV antibiotic regimens for persistent symptoms have not demonstrated sustained benefit and have identified important treatment-related risks, underscoring the need to reserve IV therapy for established indications with objective evidence of organ involvement.
Definitions and Diagnostic Criteria
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.